JP2011520918A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011520918A5 JP2011520918A5 JP2011509783A JP2011509783A JP2011520918A5 JP 2011520918 A5 JP2011520918 A5 JP 2011520918A5 JP 2011509783 A JP2011509783 A JP 2011509783A JP 2011509783 A JP2011509783 A JP 2011509783A JP 2011520918 A5 JP2011520918 A5 JP 2011520918A5
- Authority
- JP
- Japan
- Prior art keywords
- relaxin
- heart failure
- treatment
- subject
- pharmaceutically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000003743 Relaxin Human genes 0.000 claims description 86
- 108090000103 Relaxin Proteins 0.000 claims description 86
- 206010007556 Cardiac failure acute Diseases 0.000 claims description 33
- 206010013975 Dyspnoeas Diseases 0.000 claims description 28
- 208000000059 Dyspnea Diseases 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 16
- 230000002861 ventricular Effects 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 238000001990 intravenous administration Methods 0.000 claims description 12
- 238000001802 infusion Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 208000024891 symptom Diseases 0.000 claims description 6
- 230000035488 systolic blood pressure Effects 0.000 claims description 6
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 2
- 230000001771 impaired effect Effects 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 239000002171 loop diuretic Substances 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 3
- 239000002220 antihypertensive agent Substances 0.000 description 3
- 229940030600 antihypertensive agent Drugs 0.000 description 3
- 229940124549 vasodilator Drugs 0.000 description 3
- 239000003071 vasodilator agent Substances 0.000 description 3
- 206010037368 Pulmonary congestion Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 241000288140 Gruiformes Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 208000009378 Low Cardiac Output Diseases 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002057 chronotropic effect Effects 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000011863 diuretic therapy Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000002642 intravenous therapy Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 206010037833 rales Diseases 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12788908P | 2008-05-16 | 2008-05-16 | |
| US61/127,889 | 2008-05-16 | ||
| US19054508P | 2008-08-28 | 2008-08-28 | |
| US61/190,545 | 2008-08-28 | ||
| US20124008P | 2008-12-08 | 2008-12-08 | |
| US61/201,240 | 2008-12-08 | ||
| US16433309P | 2009-03-27 | 2009-03-27 | |
| US61/164,333 | 2009-03-27 | ||
| PCT/US2009/044249 WO2009140659A2 (en) | 2008-05-16 | 2009-05-15 | Method of treating dyspnea associated with acute heart failure |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012200728A Division JP5638044B2 (ja) | 2008-05-16 | 2012-09-12 | 急性心不全に伴う呼吸困難のリラキシンによる治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011520918A JP2011520918A (ja) | 2011-07-21 |
| JP2011520918A5 true JP2011520918A5 (https=) | 2012-11-01 |
| JP5651586B2 JP5651586B2 (ja) | 2015-01-14 |
Family
ID=40834101
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011509783A Expired - Fee Related JP5651586B2 (ja) | 2008-05-16 | 2009-05-15 | 急性心不全に伴う呼吸困難のリラキシンによる治療 |
| JP2012200728A Expired - Fee Related JP5638044B2 (ja) | 2008-05-16 | 2012-09-12 | 急性心不全に伴う呼吸困難のリラキシンによる治療 |
| JP2014165276A Expired - Fee Related JP5875646B2 (ja) | 2008-05-16 | 2014-08-14 | 急性心不全に伴う呼吸困難のリラキシンによる治療 |
| JP2015201153A Pending JP2016053040A (ja) | 2008-05-16 | 2015-10-09 | 急性心不全に伴う呼吸困難のリラキシンによる治療 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012200728A Expired - Fee Related JP5638044B2 (ja) | 2008-05-16 | 2012-09-12 | 急性心不全に伴う呼吸困難のリラキシンによる治療 |
| JP2014165276A Expired - Fee Related JP5875646B2 (ja) | 2008-05-16 | 2014-08-14 | 急性心不全に伴う呼吸困難のリラキシンによる治療 |
| JP2015201153A Pending JP2016053040A (ja) | 2008-05-16 | 2015-10-09 | 急性心不全に伴う呼吸困難のリラキシンによる治療 |
Country Status (30)
| Country | Link |
|---|---|
| US (7) | US8053411B2 (https=) |
| EP (2) | EP2288373B1 (https=) |
| JP (4) | JP5651586B2 (https=) |
| CN (3) | CN102036679A (https=) |
| AR (1) | AR071810A1 (https=) |
| AU (1) | AU2009246114B2 (https=) |
| BR (1) | BRPI0913011A2 (https=) |
| CA (1) | CA2724540C (https=) |
| CR (1) | CR11749A (https=) |
| CY (1) | CY1116925T1 (https=) |
| DK (1) | DK2288373T3 (https=) |
| EA (2) | EA201500552A1 (https=) |
| ES (1) | ES2546287T3 (https=) |
| GB (2) | GB2459983B (https=) |
| HK (1) | HK1202054A1 (https=) |
| HR (1) | HRP20150845T1 (https=) |
| HU (1) | HUE025483T2 (https=) |
| IL (3) | IL208992A (https=) |
| MA (1) | MA32389B1 (https=) |
| MX (1) | MX2010012450A (https=) |
| MY (2) | MY159803A (https=) |
| NZ (3) | NZ701038A (https=) |
| PL (1) | PL2288373T3 (https=) |
| PT (1) | PT2288373E (https=) |
| SG (2) | SG191587A1 (https=) |
| SI (1) | SI2288373T1 (https=) |
| TW (1) | TWI386202B (https=) |
| UA (1) | UA99953C2 (https=) |
| WO (1) | WO2009140659A2 (https=) |
| ZA (1) | ZA201007449B (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011520917A (ja) * | 2008-05-16 | 2011-07-21 | コーセラ，インコーポレーテッド | 慢性心不全の治療方法 |
| CN102036679A (zh) | 2008-05-16 | 2011-04-27 | 科尔泰拉公司 | 用松弛素治疗与急性心力衰竭相关的呼吸困难 |
| BR112012022654A2 (pt) * | 2010-03-10 | 2016-11-01 | Univ Florida | modulação de aquaporinas com relaxina |
| EP2601532B1 (en) * | 2010-08-06 | 2016-01-27 | Mycartis N.V. | Perlecan as a biomarker for renal dysfunction |
| MA34521B1 (fr) | 2010-08-17 | 2013-09-02 | Ambrx Inc | Polypeptides de relaxine modifiés et leurs utilisations |
| US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
| EP2726502A1 (en) * | 2011-07-01 | 2014-05-07 | Bayer Intellectual Property GmbH | Relaxin fusion polypeptides and uses thereof |
| WO2013059879A1 (en) * | 2011-10-26 | 2013-05-02 | Howard Florey Institute Of Experimental Physiology And Medicine | Compositions and methods for the treatment of fibrosis and fibrotic diseases |
| CN108310396B (zh) * | 2012-02-14 | 2022-07-15 | 加利福尼亚大学董事会 | 用于心血管疾病和其它病况的旁分泌基因的全身性递送和受调节的表达 |
| WO2013165606A1 (en) | 2012-05-04 | 2013-11-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modulators of the relaxin receptor 1 |
| UA117571C2 (uk) * | 2012-10-26 | 2018-08-27 | Чіесі Фармацеутічі С.П.А. | Способи контролювання кров'яного тиску та зниження диспное при серцевій недостатності |
| MX367165B (es) | 2013-04-05 | 2019-08-07 | Scpharmaceuticals Inc | Formulaciones farmacéuticas para administración subcutánea de furosemida. |
| US9707154B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| CA2935628A1 (en) * | 2014-02-03 | 2015-08-06 | Novartis Ag | Filters for infusion sets |
| EP2946788A1 (en) * | 2014-05-23 | 2015-11-25 | Immundiagnostik AG | Method and composition for treating heart failure with preserved ejection fraction |
| CN106413740A (zh) * | 2014-06-13 | 2017-02-15 | 诺华股份有限公司 | 用于降低gdf‑15的serelaxin应用 |
| WO2017100540A2 (en) | 2015-12-09 | 2017-06-15 | The California Institute For Biomedical Research | Relaxin immunoglobulin fusion proteins and methods of use |
| WO2017139164A1 (en) | 2016-02-12 | 2017-08-17 | Cardiac Pacemakers, Inc. | Systems and methods for patient monitoring |
| CN110637027B (zh) | 2017-02-08 | 2024-08-30 | 百时美施贵宝公司 | 包含药代动力学增强子的修饰的松弛素多肽及其用途 |
| US11832970B2 (en) | 2017-07-26 | 2023-12-05 | Cardiac Pacemakers, Inc. | Worsening heart failure stratification |
| CN107335051A (zh) * | 2017-08-18 | 2017-11-10 | 温州医科大学附属第医院 | 一种保护慢性心衰肾功能的药物组合物 |
| WO2020120482A1 (en) | 2018-12-10 | 2020-06-18 | Sq Innovation Ag | Pharmaceutical compositions of furosemide and uses thereof |
| EP3906019B1 (en) | 2019-01-04 | 2025-11-26 | SQ Innovation AG | Pharmaceutical compositions of furosemide |
| US12397005B2 (en) | 2019-01-04 | 2025-08-26 | Sq Innovation Ag | Pharmaceutical compositions of torsemide and uses thereof |
| EA202192129A1 (ru) | 2019-01-31 | 2021-10-19 | ЭсСиФАРМАСЬЮТИКАЛЗ ИНК. | Концентрированные жидкие фармацевтические составы фуросемида и способы их введения |
| AU2023332056A1 (en) | 2022-08-31 | 2025-03-13 | Relaxera Pharmazeutische Gesellschaft mbH & Co. KG | Immunosuppressive medicament and method of treatment |
| WO2025056188A1 (en) | 2023-09-15 | 2025-03-20 | Relaxera Pharmazeutische Gmbh & Co. Kg | Relaxin medication |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023321A (en) | 1982-12-13 | 1991-06-11 | Howard Florey Institute Of Experimental Physiology & Medicine | Molecular cloning and characterization of a further gene sequence coding for human relaxin |
| US5478807A (en) | 1991-08-19 | 1995-12-26 | Genentech, Inc. | Use of relaxin in the treatment of bradycardia |
| US5166191A (en) * | 1991-08-19 | 1992-11-24 | Genentech, Inc. | Use of relaxin in cardiovascular therapy |
| EP0707650B1 (en) | 1993-06-21 | 2003-05-21 | Genentech, Inc. | Process for producing human relaxin |
| CA2145515A1 (en) * | 1993-07-27 | 1995-02-09 | Mario Bigazzi | Use of relaxin as therapeutic or preventing agent |
| US5760069A (en) | 1995-02-08 | 1998-06-02 | Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 | Method of treatment for decreasing mortality resulting from congestive heart failure |
| US5811395A (en) | 1995-06-07 | 1998-09-22 | Medical University Of South Carolina | Relaxin analogs and derivatives methods and uses thereof |
| EP0845992B1 (en) * | 1995-08-15 | 2002-11-20 | Connetics Corporation | Use of relaxin for promoting angiogenesis |
| WO2001058468A1 (en) * | 2000-02-09 | 2001-08-16 | Connetics Corporation | Use of relaxin to treat diseases related to vasoconstriction |
| DE10155843A1 (de) * | 2000-11-16 | 2003-01-30 | Immundiagnostik Ag | Verfahren zur Prognose und Diagnose von Herzinsuffizienz |
| US20050113286A1 (en) * | 2002-03-18 | 2005-05-26 | Schreiner George F. | Methods for treating congestive heart failure |
| US7878978B2 (en) * | 2004-03-18 | 2011-02-01 | University Of Pittsburgh- Of The Commonwealth System Of Higher Education | Use of relaxin to increase arterial compliance |
| CN1968717B (zh) * | 2004-03-30 | 2013-08-21 | 延世大学教产学协力团 | 含有松弛素基因的基因送递系统和使用松弛素的药物组合物 |
| US20060264367A1 (en) | 2005-05-21 | 2006-11-23 | Howard Florey Institute | Prevention of fibrosis following cardiac injury |
| US20080077025A1 (en) | 2005-07-11 | 2008-03-27 | Leticia Delgado-Herrera | Methods for determining how to treat congestive heart failure |
| US8492329B2 (en) | 2007-07-12 | 2013-07-23 | Compugen Ltd. | Bioactive peptides and methods of using same |
| JP2011520917A (ja) | 2008-05-16 | 2011-07-21 | コーセラ，インコーポレーテッド | 慢性心不全の治療方法 |
| CN102036679A (zh) * | 2008-05-16 | 2011-04-27 | 科尔泰拉公司 | 用松弛素治疗与急性心力衰竭相关的呼吸困难 |
-
2009
- 2009-05-15 CN CN2009801177504A patent/CN102036679A/zh active Pending
- 2009-05-15 DK DK09747740.0T patent/DK2288373T3/en active
- 2009-05-15 BR BRPI0913011A patent/BRPI0913011A2/pt not_active IP Right Cessation
- 2009-05-15 EP EP09747740.0A patent/EP2288373B1/en active Active
- 2009-05-15 PT PT97477400T patent/PT2288373E/pt unknown
- 2009-05-15 SI SI200931246T patent/SI2288373T1/sl unknown
- 2009-05-15 HR HRP20150845TT patent/HRP20150845T1/hr unknown
- 2009-05-15 CN CN201610565105.0A patent/CN106177914A/zh active Pending
- 2009-05-15 ES ES09747740.0T patent/ES2546287T3/es active Active
- 2009-05-15 EP EP14167842.5A patent/EP2829280A1/en not_active Withdrawn
- 2009-05-15 US US12/467,214 patent/US8053411B2/en not_active Expired - Fee Related
- 2009-05-15 NZ NZ701038A patent/NZ701038A/en not_active IP Right Cessation
- 2009-05-15 HU HUE09747740A patent/HUE025483T2/en unknown
- 2009-05-15 PL PL09747740T patent/PL2288373T3/pl unknown
- 2009-05-15 GB GB0908432A patent/GB2459983B/en not_active Expired - Fee Related
- 2009-05-15 SG SG2013038260A patent/SG191587A1/en unknown
- 2009-05-15 CA CA2724540A patent/CA2724540C/en not_active Expired - Fee Related
- 2009-05-15 NZ NZ589009A patent/NZ589009A/en not_active IP Right Cessation
- 2009-05-15 US US12/992,356 patent/US8415301B2/en not_active Expired - Fee Related
- 2009-05-15 AR ARP090101762A patent/AR071810A1/es unknown
- 2009-05-15 NZ NZ598709A patent/NZ598709A/xx not_active IP Right Cessation
- 2009-05-15 MX MX2010012450A patent/MX2010012450A/es active IP Right Grant
- 2009-05-15 CN CN201310127326.6A patent/CN103212063B/zh not_active Expired - Fee Related
- 2009-05-15 AU AU2009246114A patent/AU2009246114B2/en not_active Ceased
- 2009-05-15 JP JP2011509783A patent/JP5651586B2/ja not_active Expired - Fee Related
- 2009-05-15 UA UAA201012879A patent/UA99953C2/uk unknown
- 2009-05-15 SG SG10201609580YA patent/SG10201609580YA/en unknown
- 2009-05-15 EA EA201500552A patent/EA201500552A1/ru unknown
- 2009-05-15 MY MYPI2010005049A patent/MY159803A/en unknown
- 2009-05-15 GB GB0918132A patent/GB2462221B/en not_active Expired - Fee Related
- 2009-05-15 TW TW098116328A patent/TWI386202B/zh not_active IP Right Cessation
- 2009-05-15 EA EA201001771A patent/EA022948B1/ru not_active IP Right Cessation
- 2009-05-15 WO PCT/US2009/044249 patent/WO2009140659A2/en not_active Ceased
-
2010
- 2010-10-19 ZA ZA2010/07449A patent/ZA201007449B/en unknown
- 2010-10-22 CR CR11749A patent/CR11749A/es unknown
- 2010-10-28 IL IL208992A patent/IL208992A/en not_active IP Right Cessation
- 2010-12-10 MA MA33418A patent/MA32389B1/fr unknown
-
2011
- 2011-05-30 HK HK15102533.3A patent/HK1202054A1/en unknown
- 2011-09-23 US US13/242,012 patent/US8372809B2/en not_active Expired - Fee Related
-
2012
- 2012-09-12 JP JP2012200728A patent/JP5638044B2/ja not_active Expired - Fee Related
-
2013
- 2013-01-04 US US13/734,301 patent/US9066916B2/en not_active Expired - Fee Related
- 2013-03-05 US US13/784,963 patent/US9205132B2/en not_active Expired - Fee Related
- 2013-09-02 IL IL228244A patent/IL228244A/en not_active IP Right Cessation
- 2013-11-28 MY MYPI2013004312A patent/MY158327A/en unknown
-
2014
- 2014-08-14 JP JP2014165276A patent/JP5875646B2/ja not_active Expired - Fee Related
-
2015
- 2015-05-28 US US14/723,701 patent/US9579363B2/en not_active Expired - Fee Related
- 2015-09-18 CY CY20151100824T patent/CY1116925T1/el unknown
- 2015-10-09 JP JP2015201153A patent/JP2016053040A/ja active Pending
-
2016
- 2016-08-18 IL IL247351A patent/IL247351A0/en unknown
-
2017
- 2017-01-23 US US15/412,447 patent/US20170151311A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011520918A5 (https=) | ||
| Taguchi et al. | Effects of enhanced external counterpulsation on hemodynamics and its mechanism relation to neurohumoral factors | |
| RU2005128124A (ru) | Фармацевтические препараты и их применение для профилактики удара, диабета и/или застойной сердечной недостаточности | |
| Weir | Diltiazem: ten years of clinical experience in the treatment of hypertension | |
| JP3336331B2 (ja) | 新生内膜形成、再狭窄、および動脈硬化の予防および処置のための薬剤としてのデスアスパラギン酸アンジオテンシンｉを使用する薬学的組成物 | |
| Figueras et al. | Prognostic implications of early spontaneous angina after acute transmural myocardial infarction | |
| Burckhartt et al. | Coronary artery slow flow associated with angina pectoris and hypotension: a case report | |
| McClean et al. | Effects of omapatrilat on systemic arterial function in patients with chronic heart failure | |
| Yeh et al. | Sodium nitroprusside as a coronary vasodilator in man: I. Effect of intracoronary sodium nitroprusside on coronary arteries, angina pectoris, and coronary blood flow | |
| CN119156218A (zh) | 用于治疗心源性休克前期和心源性休克的含有istaroxime的静脉内制剂 | |
| Bauer et al. | Rapid reduction of severe hypertension with minoxidil | |
| Aronow | Ten key points from the American College of Cardiology Foundation/American Heart Association 2011 expert consensus document on hypertension in the elderly | |
| Johnson et al. | Treatment of shock in myocardial infarction | |
| Chandraratna et al. | Use of Nitroglycerin Ointment in Congestive Heart Failure: Results of Acute and Chronic Therapy | |
| Wedeen et al. | Angiotensin II in the treatment of shock | |
| Mehta et al. | Comparison of haemodynamic effects of oral prazosin, oral hydralazine, and intravenous nitroprusside in same patients with chronic heart failure. | |
| Koliopoulos et al. | Pinacidil, a new vasodilator, in the treatment of patients with moderate to severe hypertension | |
| Laakshmi | Non-Pharmacological Therapies for Treatment of Heart Failure-An Update | |
| Weiss et al. | The Never-Ending Story of Complicated Hypertension | |
| Houde et al. | Indapamide for out-patient treatment of hypertension: modifications in serum catecholamine levels | |
| Ikram et al. | Haemodynamic effects of dobutamine in patients with congestive heart failure receiving captopril. | |
| Kramer et al. | Controlled trial of captopril for heart failure: Effects on hemodynamics, scintigraphy and exercise tolerance | |
| Hill et al. | Orthostatic Hypotension following Right Ventricular Myocardial Infarction Corrected with Mineralocorticoid Therapy | |
| Cody et al. | Captopril pharmacokinetics in chronic heart failure: correlation with acute hemodynamic and hormonal response | |
| Sharp et al. | Nesiritide for treatment of heart failure due to right ventricular dysfunction |